**Table H19. Evidence table (Reference ID #497)**

| Study Description | Intervention(s)/ Comparator(s) | Patient Population | Baseline Measure(s) | Outcome Measure(s) | Quality |
| --- | --- | --- | --- | --- | --- |
| **Author:**  Rigotti et al., 2006  **Country:**  USA  **Enrollment period:**  September 2001 to  July 2004  **Intervention setting:**  Managed care organization and community based prenatal practices  **Funding:**  Federal grant and Robert Wood Johnson  **Author industry relationship disclosures:**  NR  **Study Design:**  RCT  **Blinding:**  None | **Intervention:**  Proactive, pregnancy tailored telephone counseling intervention, series of telephone calls accompanied by additional written materials.  **Intervention provider:**  Counselors  **Intervention setting:**  Home  **Comparator:**  Best practice (control)  **Followup:**  End of pregnancy and 3 months post-partum  Assessment by telephone interview (conducted by research assistant). Participants who reported nonsmoking for past 7 days were asked to mail in saliva sample and received $50 for each sample.  **Groups:**  **G1:** Telephone counseling  **G2:** Control | **Inclusion criteria:**   * Pregnant women ≤ 26 weeks gestation * Smoked at least 1 cigarette in past 7 days * Age 18 or older * Willing to consider altering their smoking during pregnancy * Reachable by telephone * English speaking * Expected to live in New England for next year   **Enrollment, n:**  **G1:** 220  **G2:** 222  **Followup, n:**  End of pregnancy  **G1:** 152  **G2:** 156  Postpartum assessment  **G1:** 141  **G2:** 152  Intention to treat analysis for end of pregnancy  **G1:** 209  **G2:** 212  Intention to treat analysis for 3 months postpartum  **G1:** 209  **G2:** 210  **Age, mean years ± SD:**  **G1:** 28.9 ± 6.7  **G2:** 28.1 ± 5.8  **Education, mean years ± SD:**  **G1:** 13.1 ± 2.2  **G2:** 13.0 ± 1.9  **Gestation, mean weeks ± SD:**  **G1:** 13.1 ± 4.8  **G2:** 12.2 ± 4.4  **Insurance status, n (%):**  Private  **G1:** 166 (75)  **G2:** 156 (70)  Public  **G1:** 44 (20)  **G2:** 52 (23)  Other  **G1:** 10 (5)  **G2:** 14 (6)  **Parity, n (%):**  Nulliparous  **G1:** 112 (51)  **G2:** 94 (42)  **Race/ethnicity, n (%):**  Non-Hispanic white  **G1:** 194 (88)  **G2:** 192 (87)  **Partner status, n (%):**  Married or living with partner  **G1:** 167 (76)  **G2:** 158 (71)  **Partner smoking status, n (%):**  Smoker  **G1:** 149 (71)  **G2:** 130 (62)  **Socioeconomic status, n (%):**  Employed in past year  **G1:** 192 (87)  **G2:** 201 (91)  **Smoking history:**  Age started smoking regularly, mean age ± SD  **G1:** 15.3 ± 3.0  **G2:** 15.2 ± 2.9  Cigarettes smoked per day before current pregnancy, mean number ± SD  **G1:** 20.9 ± 9.1  **G2:** 20.8 ± 8.3  First morning cigarette within 30 minutes, n (%)  **G1:** 100 (45)  **G2:** 89 (40)  Made quit attempt in this pregnancy, n (%)  **G1:** 113 (51)  **G2:** 91 (41)  Plan to quit in next 30 days, n (%)  **G1:** 188 (86)  **G2:** 181 (82) | **Maternal smoking status**  Number of cigarettes per day, mean ± SD:  **G1:** 10.4 ± 7.4  **G2:** 10.0 ± 7.1 | **Maternal smoking status**  Abstinence at end of pregnancy, n (%):  **G1:** 21 (10.0)  **G2:** 16 (7.5)  **G1 vs. G2:** OR=1.37 (95% CI: 0.69 to 2.70),p=0.39  Abstinence at 3 months postpartum, n (%):  **G1:** 14 (6.7)  **G2:** 15 (7.1)  **G1 vs. G2:** OR=0.93 (95% CI: 0.44 to 1.99), p**=**1.00  Abstinence at end of pregnancy and at 3 months postpartum[[1]](#footnote-1), n (%):  **G1:** 10 (4.8)  **G2:** 7 (3.3)  **G1 vs. G2:** OR=1.46 (95% CI: 0.54 to 3.90), p=0.47  Relapse:  NR  **Child/infant outcomes**  NR  **Adverse events:**  NR | **Overall quality:**  Good  **Risk of bias**  Randomization:  Low  Allocation concealment:  Low  Selective reporting:  Low  Blinding patients/personnel:  Low  Blinding outcome assessment:  Low  Incomplete outcome reporting:  Low  Other:  Low |

Notes: Paper also reports subgroup analysis by baseline characteristics (cigarettes/day at study entry; made quit attempt since start of pregnancy; confidence in ability to quit; spouse smoking status.

1. Cotinine validated at both timepoints [↑](#footnote-ref-1)